SCHEMBL3973309

SCHEMBL3973309

O=C1NC2(c3ccccc3)NC(=O)NC2(c2ccccc2)N1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 4/20 0.52
ALDH1A1 P00352 2/20 0.52
BLM P54132 2/20 0.52
PMP22 Q01453 2/20 0.52
CACNA1F O60840 1/20 0.52
MAPT P10636 1/20 0.52
HTR2A P28223 1/20 0.52
HRH1 P35367 1/20 0.52
SCN1A P35498 1/20 0.52
SCN4A P35499 1/20 0.52
CACNA1D Q01668 1/20 0.52
KCNH2 Q12809 1/20 0.52
CACNA1S Q13698 1/20 0.52
CACNA1C Q13936 1/20 0.52
SCN5A Q14524 1/20 0.52
SCN2A Q99250 1/20 0.52
SCN3A Q9NY46 1/20 0.52
PKM P14618 1/20 0.50
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975525 0.84 MMP2 (0.48) CYP2C9ALDH1A1BLMPMP22CACNA1F
SCHEMBL3968265 0.75 CNR1 (0.39) CYP2C9ALDH1A1BLMPMP22CACNA1F
SCHEMBL16253385 0.75 SMN1; SMN2 (0.50) CYP2C9ALDH1A1BLMPMP22CACNA1F
SCHEMBL9717767 0.74 ALDH1A1 (0.37) CYP2C9ALDH1A1BLMPMP22CACNA1F
SCHEMBL14354280 0.69 CYP2C9 (0.63) CYP2C9ALDH1A1BLMPMP22CACNA1F
Phenytoin SCHEMBL5499612 0.69 CYP2C9 (1.00) CYP2C9ALDH1A1BLMPMP22CACNA1F
Phenytoin SCHEMBL3440 0.69 CYP2C9 (1.00) CYP2C9ALDH1A1BLMPMP22CACNA1F
Phenytoin SCHEMBL2905857 0.67 CYP2C9 (0.96) CYP2C9ALDH1A1BLMPMP22CACNA1F
Phenytoin SCHEMBL2140317 0.67 CYP2C9 (0.96) CYP2C9ALDH1A1BLMPMP22CACNA1F
Phenytoin SCHEMBL1461588 0.67 CYP2C9 (0.96) CYP2C9ALDH1A1BLMPMP22CACNA1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165658-A1 PROCESS FOR THE PREPARATION OF IODIDES TECHNION R&D FOUNDATION LTD. (IL) 2013-06-27 US claimed
WO-2011154953-A1 PROCESS FOR THE PREPARATION OF IODIDES TECHNION R&D FOUNDATION LTD. (IL) 2011-12-15 WO claimed
EP-4748869-A1 EPOXY RESIN COMPOSITION, ADHESIVE AGENT, SEALING MATERIAL, CURED ARTICLE, SEMICONDUCTOR DEVICE, AND ELECTRONIC COMPONENT Namics Corporation (JP) 2026-05-27 EP disclosed
EP-4748870-A1 EPOXY RESIN COMPOSITION, ADHESIVE, SEALING MATERIAL, CURED PRODUCT, SEMICONDUCTOR DEVICE, AND ELECTRONIC COMPONENT Namics Corporation (JP) 2026-05-27 EP disclosed
EP-4748893-A1 PHOTOCURABLE RESIN COMPOSITION, ADHESIVE, SEALING MATERIAL, COATING AGENT, CURED PRODUCT, SEMICONDUCTOR DEVICE, ELECTRONIC COMPONENT, AND CURING, BONDING, SEALING, AND COATING METHODS USING PHOTOCURABLE RESIN COMPOSITION Namics Corporation (JP) 2026-05-27 EP disclosed
EP-4372030-B1 CURABLE RESIN COMPOSITION NAMICS CORP (JP) 2026-03-25 EP disclosed
US-12565608-B2 Thermally conductive resin composition SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-03-03 US disclosed
EP-4613731-A1 HALOETHER, METHOD FOR PRODUCING SAME, VINYL ETHER, AND METHOD FOR PRODUCING SAME DAIKIN INDUSTRIES, LTD. (JP) 2025-09-10 EP disclosed
EP-4608891-A1 RESIN COMPOSITION, ADHESIVE, SEALANT, CURED PRODUCT, SEMICONDUCTOR DEVICE AND ELECTRONIC COMPONENT Namics Corporation (JP) 2025-09-03 EP disclosed
EP-4609432-A1 RESIN COMPOSITION, ADHESIVE, SEALANT, CURED PRODUCT AND SEMICONDUCTOR DEVICE Namics Corporation (JP) 2025-09-03 EP disclosed
WO-2025126839-A1 RESIN COMPOSITION, ADHESIVE AGENT, SEALING MATERIAL, CURED PRODUCT, SEMICONDUCTOR DEVICE, AND ELECTRONIC COMPONENT ナミックス株式会社 2025-06-19 WO disclosed
US-20130165658-A1 PROCESS FOR THE PREPARATION OF IODIDES TECHNION R&D FOUNDATION LTD. (IL) 2013-06-27 US disclosed
WO-2011154953-A1 PROCESS FOR THE PREPARATION OF IODIDES TECHNION R&D FOUNDATION LTD. (IL) 2011-12-15 WO disclosed
EP-1668012-B1 METHOD FOR PREPARING CUCURBITURILS NEWSOUTH INNOVATIONS PTY LTD (AU) 2011-12-14 EP disclosed
US-7501523-B2 reacting an oligomer consisting of 2-11 linked glycolurils or analogues with one or more compounds selected from glycoluril, glycoluril analogues and/or oligomers of glycoluril or glycoluril analogues, in the presence of an acid, and a template (dimethylaminobenzaldehyde) to form a cucurbit(n)uril NEWSOUTH INNOVATIONS PTY LIMITED (AU) 2009-03-10 US disclosed
US-20070287836-A1 Method for Preparing Compounds Comprising Cucurbituril Groups NEWSOUTH INNOVATIONS PTY LIMITED (AU) 2007-12-13 US disclosed
US-20070066818-A1 Method for preparing cucurbiturils ANTHONY IVAN DAY (AU) 2007-03-22 US disclosed
EP-0213570-B1 GLYCOLURILE DERIVATIVES AND THEIR USE AS POLYMER STABILIZERS BASF Aktiengesellschaft (DE) 1992-04-08 EP disclosed
US-4769457-A Glycoluril derivatives and their use as stabilizers for polymers BASF AKTIENGESELLSCHAFT (DE) 1988-09-06 US disclosed
EP-0213570-A2 Glycolurile derivatives and their use as polymer stabilizers BASF Aktiengesellschaft (DE) 1987-03-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12565608-B2 Thermally conductive resin composition ITGAM, RAE1, FCGR1A CYP2C9 3024/4885ALDH1A1 840/4885BLM 1931/4885
US-20070287836-A1 Method for Preparing Compounds Comprising Cucurbituril Groups ACSL6, AGL, LIPA CYP2C9 262/4885ALDH1A1 93/4885BLM 1946/4885
US-20070066818-A1 Method for preparing cucurbiturils AGL, UGCG, MGLL CYP2C9 2278/4885ALDH1A1 1186/4885BLM 3968/4885
US-20130165658-A1 PROCESS FOR THE PREPARATION OF IODIDES NISCH, TPO, HDHD5 CYP2C9 44/4885ALDH1A1 281/4885BLM 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.